--- title: "GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT" type: "News" locale: "en" url: "https://longbridge.com/en/news/278212232.md" description: "GW&K Investment Management LLC increased its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 9.1% in Q3, owning 1,144,330 shares valued at approximately $13.47 million. Other institutional investors also raised their holdings, with Frazier Life Sciences Management L.P. increasing by 23.3%. Phathom's stock is currently down 0.7%, trading at $10.67, with a market cap of $840.80 million. Analysts have mixed ratings, with a consensus price target of $22.25. Phathom focuses on developing treatments for gastrointestinal diseases, with its lead asset being vonoprazan." datetime: "2026-03-07T10:47:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278212232.md) - [en](https://longbridge.com/en/news/278212232.md) - [zh-HK](https://longbridge.com/zh-HK/news/278212232.md) --- # GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT GW&K Investment Management LLC boosted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 9.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,144,330 shares of the company's stock after buying an additional 95,858 shares during the quarter. GW&K Investment Management LLC owned approximately 1.61% of Phathom Pharmaceuticals worth $13,469,000 at the end of the most recent reporting period. A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Frazier Life Sciences Management L.P. increased its holdings in Phathom Pharmaceuticals by 23.3% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 12,466,489 shares of the company's stock worth $119,554,000 after purchasing an additional 2,357,210 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Phathom Pharmaceuticals by 13.4% during the second quarter. Invesco Ltd. now owns 4,140,072 shares of the company's stock valued at $39,703,000 after purchasing an additional 489,260 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Phathom Pharmaceuticals by 15.4% during the third quarter. Vanguard Group Inc. now owns 3,215,572 shares of the company's stock worth $37,847,000 after purchasing an additional 428,261 shares during the last quarter. 683 Capital Management LLC grew its holdings in shares of Phathom Pharmaceuticals by 45.7% during the second quarter. 683 Capital Management LLC now owns 2,105,000 shares of the company's stock worth $20,187,000 after purchasing an additional 660,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Phathom Pharmaceuticals by 5.3% in the second quarter. Geode Capital Management LLC now owns 1,069,927 shares of the company's stock valued at $10,263,000 after buying an additional 53,504 shares during the period. Institutional investors own 99.01% of the company's stock. ## Phathom Pharmaceuticals Stock Down 0.7% Shares of NASDAQ:PHAT opened at $10.67 on Friday. Phathom Pharmaceuticals, Inc. has a twelve month low of $2.21 and a twelve month high of $18.31. The stock's 50 day moving average is $13.62 and its 200-day moving average is $13.50. The firm has a market capitalization of $840.80 million, a price-to-earnings ratio of -3.49 and a beta of 0.51. Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The business had revenue of $57.58 million for the quarter, compared to the consensus estimate of $57.44 million. Equities research analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.78 earnings per share for the current fiscal year. ## Wall Street Analyst Weigh In PHAT has been the subject of several analyst reports. Stifel Nicolaus set a $28.00 target price on Phathom Pharmaceuticals in a research report on Thursday, February 26th. Guggenheim raised their price objective on Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, February 27th. Raymond James Financial assumed coverage on Phathom Pharmaceuticals in a report on Thursday, December 11th. They issued a "strong-buy" rating and a $28.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Phathom Pharmaceuticals in a report on Thursday, January 22nd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $22.25. **Check Out Our Latest Stock Report on PHAT** ## About Phathom Pharmaceuticals (Free Report) Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom's research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist. The company's lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States. ## Read More - Five stocks we like better than Phathom Pharmaceuticals - The gold chart Wall Street is terrified of… - America’s 1776 happening again - What a Former CIA Agent Knows About the Coming Collapse - Unlocked: Elon Musk’s Next Big IPO - Elon Musk already made me a “wealthy man” **Want to see what other hedge funds are holding PHAT?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report). _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Phathom Pharmaceuticals Right Now? Before you consider Phathom Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list. While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [PHAT.US](https://longbridge.com/en/quote/PHAT.US.md) ## Related News & Research - [AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization](https://longbridge.com/en/news/283037094.md) - [Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT](https://longbridge.com/en/news/281495979.md) - [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md) - [Danaher Corporation (NYSE:DHR) Short Interest Up 25.0% in March](https://longbridge.com/en/news/283039047.md) - [Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)](https://longbridge.com/en/news/283014601.md)